The objective of this study is to evaluate the association between antineutrophil cytoplasmic autoantibody (ANCA) subtype and ANCA titers on clinical outcomes and disease activity among a cohort of patients from Central Appalachia diagnosed with ANCA-associated vasculitis (AAV) over a 3-decade period. This is a retrospective chart review of all patients diagnosed with AAV. ANCA subtypes (myeloperoxidase (MPO) and proteinase 3 (PR3)) and titers at the time of diagnosis and at the time of relapse or last follow-up were evaluated along with patient outcomes. Outcomes of interest included relapse, development of end-stage renal disease (ESRD) and mortality. Sensitivity analysis and multivariable analysis were performed. Of the 202 patients, 111 patients were MPO-ANCA positive and 91 patients were PR3-ANCA positive. Relapse was more frequent among patients with PR3-ANCA compared to MPO-ANCA (35% vs 12%, p < 0.001). In both ANCA subgroups, the strongest predictor of relapse was an increase in titers prior to relapse, HR 8.1 (95% CI 1.6–40), p 0.009. Patients who achieved serological remission had a lower risk of ESRD [sub-HR 0.31 (95% CI 0.11–0.89)] and mortality [HR (95% CI) 0.24 (0.07–0.7)]. PR3-ANCA was associated with higher risk of ESRD [sub-HR 3.1 (95% CI 1.1–8.5)]. There was no difference in mortality between patients with MPO-ANCA and PR3-ANCA. Our study supports the use of both ANCA subtypes and titer levels for predicting clinical outcomes in patients receiving treatment for AAV. Monitoring of ANCA antibody titers may be useful since both serological remission and increase in titers provide prognostic information.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Watts RA, Mahr A, Mohammad AJ, Gatenby P, Basu N, Flores-Suárez LF (2015) Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant 30(Suppl 1):14–22. https://doi.org/10.1093/ndt/gfv022
Davies DJ, Moran JE, Niall JF, Ryan GB (1982) Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed) 285:606. https://doi.org/10.1136/bmj.285.6342.606
Brix SR, Noriega M, Tennstedt P, Vettorazzi E, Busch M, Nitschke M et al (2018) Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int 94:1177–1188. https://doi.org/10.1016/j.kint.2018.07.020
van Daalen EE, Wester Trejo MAC, Göçeroğlu A, Ferrario F, Joh K, Noël LH et al (2020) Developments in the histopathological classification of ANCA-associated glomerulonephritis. Clin J Am SocNephrol 15:1103–1111. https://doi.org/10.2215/CJN.14561119
Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G et al (1998) Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 53:743–753. https://doi.org/10.1046/j.1523-1755.1998.00807.x
Craven A, Robson J, Ponte C, Grayson PC, Suppiah R, Judge A et al (2013) ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). ClinExpNephrol 17:619–621. https://doi.org/10.1007/s10157-013-0854-0
Kallenberg CG (2010) Pathophysiology of ANCA-associated small vessel vasculitis. CurrRheumatol Rep 12:399–405. https://doi.org/10.1007/s11926-010-0138-6
Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O et al (2012) Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 71:955–960. https://doi.org/10.1136/annrheumdis-2011-200477
Group WsGETWR (2005) Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 352:351–361. https://doi.org/10.1056/NEJMoa041884
Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CG et al (2000) Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 43:2025–2033. https://doi.org/10.1002/1529-0131(200009)43:9%3c2025::AID-ANR13%3e3.0.CO;2-O
Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA (2006) Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCAtitres to treatment. Rheumatology (Oxford) 45:724–729. https://doi.org/10.1093/rheumatology/kei272
Terrier B, Saadoun D, Sène D, Ghillani P, Amoura Z, Deray G et al (2009) Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides. Ann Rheum Dis 68:1564–1571. https://doi.org/10.1136/ard.2008.094714
Watanabe H, Sada KE, Matsumoto Y, Harigai M, Amano K, Dobashi H et al (2018) Association between reappearance of myeloperoxidase-antineutrophil cytoplasmic antibody and relapse in antineutrophil cytoplasmic antibody-associated vasculitis: subgroup analysis of nationwide prospective cohort studies. Arthritis Rheumatol 70:1626–1633. https://doi.org/10.1002/art.40538
Kemna MJ, Damoiseaux J, Austen J, Winkens B, Peters J, van Paassen P et al (2015) ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J Am SocNephrol 26:537–542. https://doi.org/10.1681/ASN.2013111233
Finkielman JD, Merkel PA, Schroeder D, Hoffman GS, Spiera R, St Clair EW et al (2007) Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 147:611–619. https://doi.org/10.7326/0003-4819-147-9-200711060-00005
Nowack R, Grab I, Flores-Suarèz LF, Schnülle P, Yard B, van der Woude FJ (2001) ANCAtitres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 16:1631–1637. https://doi.org/10.1093/ndt/16.8.1631
Kyndt X, Reumaux D, Bridoux F, Tribout B, Bataille P, Hachulla E et al (1999) Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 106:527–533. https://doi.org/10.1016/s0002-9343(99)00064-9
Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA (2012) Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis—a meta-analysis. Rheumatology (Oxford) 51:100–109. https://doi.org/10.1093/rheumatology/ker280
Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1–11. https://doi.org/10.1002/art.37715
Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP et al (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33:1101–1107. https://doi.org/10.1002/art.1780330807
Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W et al (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222–227. https://doi.org/10.1136/ard.2006.054593
Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K et al (2011) The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 80:17–28. https://doi.org/10.1038/ki.2010.483
Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA et al (2014) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 63:713–735. https://doi.org/10.1053/j.ajkd.2014.01.416
Hilhorst M, van Paassen P, Tervaert JW, Registry LR (2015) Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis. J Am SocNephrol 26:2314–2327. https://doi.org/10.1681/ASN.2014090903
Berti A, Cornec-Le Gall E, Cornec D, Casal Moura M, Matteson EL, Crowson CS et al (2019) Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. Nephrol Dial Transplant 34:1508–1517. https://doi.org/10.1093/ndt/gfy250
Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC et al (2005) Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143:621–631. https://doi.org/10.7326/0003-4819-143-9-200511010-00005
Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD (2004) ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 19:1403–1411. https://doi.org/10.1093/ndt/gfh161
Mohammad AJ, Segelmark M (2014) A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis. J Rheumatol 41:1366–1373. https://doi.org/10.3899/jrheum.131038
de Joode AA, Sanders JS, Stegeman CA (2013) Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am SocNephrol 8:1709–1717. https://doi.org/10.2215/CJN.01020113
Berti A, Cornec D, Crowson CS, Specks U, Matteson EL (2017) The epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in Olmsted county, Minnesota: a 20-year US population-based study. Arthritis Rheumatol 69:2338–2350. https://doi.org/10.1002/art.40313
Solans-Laqué R, Fraile G, Rodriguez-Carballeira M, Caminal L, Castillo MJ, Martínez-Valle F et al (2017) Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity. Medicine (Baltimore) 96:e6083. https://doi.org/10.1097/MD.0000000000006083
Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS (1993) Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener’s granulomatosis. Arthritis Rheum 36:365–371. https://doi.org/10.1002/art.1780360312
He P, Hu J-P, Tian X-J, He L-J, Sun S-R, Huang C (2020) Prevalence and risk factors of relapse in patients with ANCA-associated vasculitis receiving cyclophosphamide induction: a systematic review and meta-analysis of large observational studies. Rheumatology. https://doi.org/10.1093/rheumatology/keaa667
Conflict of interest
The authors declare that they have no conflict of interest.
This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of West Virginia University approved this study. IRB approval number: 1905572870.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Aljuhani, M., Makati, D., Hoff, A. et al. Antibody subtypes and titers predict clinical outcomes in ANCA-associated vasculitis. Rheumatol Int (2021). https://doi.org/10.1007/s00296-021-04802-w
- ANCA-associated vasculitis
- Clinical outcomes
- End-stage renal disease
- ANCA subtypes
- ANCA titers
- Serological remission